Latest Ratios: P/E Ratio 256.9x · EV/EBITDA 73.1x · ROE 2.2%. (2004–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $448M | $187M | $191M | $218M | $278M | $187M | $736M | — | — | — | — |
| Enterprise Value | $425M | $167M | $184M | $157M | $94M | $201M | $643M | — | — | — | — |
| P/E Ratio → | 256.88 | 124.00 | — | — | 4.07 | — | — | — | — | — | — |
| P/S Ratio | 5.75 | 2.79 | 6.70 | 10.80 | 3.47 | 243.82 | 23.87 | — | — | — | — |
| P/B Ratio | 5.59 | 2.70 | 2.82 | 2.31 | 2.33 | — | 8.76 | — | — | — | — |
| P/FCF | 27.10 | 13.14 | — | — | 2.80 | — | — | — | — | — | — |
| P/OCF | 25.35 | 12.29 | — | — | 2.78 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.50 | 6.43 | 7.79 | 1.17 | 262.98 | 20.85 | — | — | — | — |
| EV / EBITDA | 73.07 | 33.41 | — | — | 2.71 | — | — | — | — | — | — |
| EV / EBIT | 111.46 | 25.25 | — | — | 2.91 | — | — | — | — | — | — |
| EV / FCF | — | 11.76 | — | — | 0.94 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.6% | 99.6% | 98.8% | 98.8% | 99.8% | 73.6% | 99.4% | -2587.0% | -1789.0% | -598.9% | -266.4% |
| Operating Margin | 4.9% | 4.9% | -93.1% | -135.1% | 39.7% | -10836.2% | -187.5% | -100701.4% | -48046.6% | -12027.5% | -3354.1% |
| Net Profit Margin | 2.2% | 2.2% | -101.2% | -117.5% | 84.0% | -13231.5% | -211.2% | -115247.8% | -49664.4% | -11854.6% | -3251.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.2% | 2.2% | -35.6% | -22.2% | 130.7% | -298.1% | -124.1% | -127.1% | -47.4% | -34.0% | -27.2% |
| ROA | 0.9% | 0.9% | -14.8% | -9.5% | 28.0% | -39.8% | -24.2% | -30.4% | -25.5% | -28.6% | -22.0% |
| ROIC | 4.5% | 4.5% | -42.4% | -60.5% | — | — | — | — | — | — | -1305.9% |
| ROCE | 3.1% | 3.1% | -17.1% | -13.8% | 16.5% | -38.2% | -25.3% | -30.5% | -27.3% | -32.6% | -25.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.90 | 0.90 | 1.03 | 0.80 | 0.62 | — | 2.18 | 8.10 | 1.57 | 0.04 | 0.10 |
| Debt / EBITDA | 12.41 | 12.41 | — | — | 2.15 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.11 | -0.64 | -1.55 | — | -1.11 | -1.80 | -1.06 | -1.02 | -0.98 |
| Net Debt / EBITDA | -3.93 | -3.93 | — | — | -5.34 | — | — | — | — | — | — |
| Debt / FCF | — | -1.38 | — | — | -1.86 | — | — | — | — | — | — |
| Interest Coverage | 1.38 | 1.38 | -5.14 | -6.27 | 6.49 | -6.50 | -4.74 | -6.33 | -24.31 | -277.71 | — |
Net cash position: cash ($82M) exceeds total debt ($62M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 2.94 | 4.02 | 4.27 | 5.95 | 6.68 | 5.56 | 10.46 | 9.22 | 7.75 |
| Quick Ratio | 1.23 | 1.23 | 2.94 | 4.02 | 4.27 | 5.95 | 6.68 | 5.56 | 10.46 | 9.22 | 7.75 |
| Cash Ratio | 1.09 | 1.09 | 2.02 | 3.57 | 4.12 | 5.51 | 6.36 | 5.28 | 10.10 | 8.67 | 6.98 |
| Asset Turnover | — | 0.44 | 0.16 | 0.09 | 0.28 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventory Turnover | 75.00 | 75.00 | 85.25 | 62.00 | 40.25 | 50.50 | 44.25 | 463.50 | 557.25 | 141.79 | 68.96 |
| Days Sales Outstanding | — | 41.21 | 417.93 | 287.48 | 32.99 | 5686.84 | 142.43 | 2089.49 | 1289.87 | 10788.06 | 4160.45 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.4% | 0.8% | — | — | 24.6% | — | — | — | — | — | — |
| FCF Yield | 3.7% | 7.6% | — | — | 35.7% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $50M | $50M | $50M | $56M | $39M | $37M | $31M | $31M | $27M | $25M |
Binary clinical milestone dependency
As reported in recent financial data, GNFT trades at a P/S ratio of 5.75 and an EV/EBITDA of 73.07, suggesting that market participants are pricing in significant future royalty potential rather than current, milestone-dependent earnings, which warrants caution given the inherent volatility of clinical-stage biotechnology valuations.
The elevated P/E of 256.88 appears to be a byproduct of minimal current earnings rather than a reflection of long-term value, as the company remains in a transition phase. Investors should note that these multiples are highly sensitive to the timing of milestone recognition, which may lead to significant valuation swings that do not necessarily correlate with underlying operational progress.
Based on the company's reported figures, the ROIC has fluctuated wildly, reaching 0.1% in 2025Q2 after a -27.4% reading in 2024Q4, which indicates that GNFT is currently struggling to generate meaningful returns on its invested capital while it continues to fund high-cost, long-term clinical development programs.
The erratic nature of these returns suggests that the company's capital allocation is currently dominated by the necessity of funding R&D rather than optimizing for immediate profitability. This trend implies that until the company achieves a consistent royalty stream, ROIC will likely remain a secondary metric compared to the preservation of the cash runway.
According to historical financial statements, GNFT's cash conversion cycle has shown extreme instability, including a -1479 day reading in 2025Q2, which highlights the company's reliance on lumpy milestone payments that distort standard working capital metrics and make traditional efficiency analysis largely inapplicable to its current business model.
The massive swings in DSO and DPO suggest that the company's operational efficiency is secondary to the timing of contractual payments from partners like Ipsen. Analysts should focus on the cash burn rate rather than working capital turnover, as the latter is heavily influenced by non-recurring accounting events.
As indicated by recent filings, GNFT's debt-to-equity ratio has increased to 2.65 in 2025Q2 from 0.90 in 2024Q4, suggesting that the company is increasingly utilizing debt to bridge the gap between milestone-driven revenue and the persistent, high-cost requirements of its ongoing clinical trial pipeline.
While the current debt levels appear manageable, the trend toward higher leverage warrants close monitoring, especially if clinical milestones are delayed. The lack of consistent interest coverage suggests that the company remains vulnerable to liquidity constraints if it cannot secure non-dilutive funding or additional partnership milestones.
Investors frequently misapply traditional P/E and operating margin metrics to GNFT, failing to recognize that these ratios are heavily distorted by the lumpy, non-recurring nature of milestone payments, which obscures the underlying cash burn and the true economic reality of the company's clinical-stage business model.
Instead of relying on GAAP earnings, analysts should prioritize adjusted cash burn and the probability-weighted value of future royalty streams. Using standard profitability ratios for a company in this phase of development may lead to an inaccurate assessment of its long-term viability and capital requirements.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GNFT stock.
Genfit S.A.'s current P/E ratio is 256.9x. The historical average is 64.0x. This places it at the 100th percentile of its historical range.
Genfit S.A.'s current EV/EBITDA is 73.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.1x.
Genfit S.A.'s return on equity (ROE) is 2.2%. The historical average is -52.4%.
Based on historical data, Genfit S.A. is trading at a P/E of 256.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Genfit S.A. has 99.6% gross margin and 4.9% operating margin.
Genfit S.A.'s Debt/EBITDA ratio is 12.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.